Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (15175)	2/17/1998 12:23:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Andy, LGND's cheat sheet (linked to Research Magazine in home.att.net ) shows Actinic Keratosis under potential markets (1.5 million cases) for Targretin, but I'm not sure about the specific clinicals for that indication (but I seem to remember it being in Phase II, so I suspect that there is some initial data). I haven't seen any skin cancer (other than CTCL or KS which are cancers that present externally), but obviously, LGND could attack the problem with gel or oral formulations.